# Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastases

> **NCT05807893** · PHASE2,PHASE3 · COMPLETED · sponsor: **Sun Yat-sen University** · enrollment: 40 (actual)

## Conditions studied

- Non-small Cell Lung Cancer Stage II
- Bevacizumab
- Immunotherapy
- Brain Metastases

## Interventions

- **DRUG:** Serplulimab combined with bevacizumab and first-line chemotherapy

## Key facts

- **NCT ID:** NCT05807893
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-14
- **Primary completion:** 2024-03-22
- **Final completion:** 2024-05-15
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2024-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05807893

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05807893, "Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastases". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05807893. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*